Kintara Therapeutics (KTRA) Short Interest Ratio & Short Volume → He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad) Free KTRA Stock Alerts $0.15 -0.01 (-6.31%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Kintara Therapeutics Short Interest DataCurrent Short Volume700,000 sharesPrevious Short Volume658,900 sharesChange Vs. Previous Month+6.24%Dollar Volume Sold Short$77,070.00Short Interest Ratio / Days to Cover0.1Last Record DateApril 15, 2024Outstanding Shares39,040,000 sharesPercentage of Shares Shorted1.79%Today's Trading Volume2,126,124 sharesAverage Trading Volume12,825,286 sharesToday's Volume Vs. Average17% Short Selling Kintara Therapeutics ? Sign up to receive the latest short interest report for Kintara Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatKTRA Short Interest Over TimeKTRA Days to Cover Over TimeKTRA Percentage of Float Shorted Over Time Ad American Hartford Gold GroupTrump Asset Seizure Threat Alert: Could Your Savings Be Next?Trump Asset Seizures Threat A Warning For 401K Owners?Request Your FREE WEALTH PROTECTION GUIDE Kintara Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2024700,000 shares $77,070.00 +6.2%N/A0.1 $0.11 3/31/2024658,900 shares $68,525.60 -70.1%N/A0 $0.10 3/15/20242,200,000 shares $207,020.00 +0.5%N/A0.2 $0.09 2/29/20242,190,000 shares $234,330.00 +432.7%N/A0.2 $0.11 2/15/2024411,100 shares $44,028.81 +150.7%N/A0 $0.11 1/31/2024164,000 shares $23,747.20 -59.7%5.0%0 $0.14 Get the Latest News and Ratings for KTRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/2024407,100 shares $56,953.29 +234.8%12.3%0.1 $0.14 12/31/2023121,600 shares $20,623.36 -60.4%3.7%0 $0.17 12/15/2023306,900 shares $60,766.20 -12.8%9.3%0.3 $0.20 11/30/2023352,000 shares $119,680.00 -34.6%10.9%0.5 $0.34 11/15/2023538,500 shares $189,228.90 +541.8%32.3%1.3 $0.35 10/31/202383,900 shares $62,664.91 +126.2%5.0%0.6 $0.75 10/15/202337,100 shares $127,253.00 +152.4%2.2%2.1 $3.43 9/30/202314,700 shares $59,388.00 +53.1%0.9%0.9 $4.04 9/15/20239,600 shares $39,936.00 -66.6%0.6%0.1 $4.16 8/31/202328,700 shares $130,585.00 +38.0%1.8%0.2 $4.55 8/15/202320,800 shares $68,640.00 -23.3%1.2%0.1 $3.30 7/31/202327,100 shares $120,866.00 -46.6%1.6%0.2 $4.46 7/15/202350,700 shares $235,248.00 -9.8%3.1%0.3 $4.64 6/30/202356,200 shares $226,486.00 +200.5%3.4%0.3 $4.03 6/15/202318,700 shares $70,125.00 -26.4%1.1%0.5 $3.75 5/31/202325,400 shares $81,534.00 +75.2%1.5%0.6 $3.21 5/15/202314,500 shares $43,500.00 +12.4%0.9%0.3 $3.00 4/30/202312,900 shares $35,733.00 -41.9%0.8%0.3 $2.77 4/15/202322,200 shares $63,025.80 -12.9%1.4%0.9 $2.84 3/31/202325,500 shares $89,989.50 +390.4%1.6%0.9 $3.53 3/15/20235,200 shares $17,108.00 -85.4%0.3%0.1 $3.29 2/28/202335,600 shares $177,644.00 +65.6%2.2%0.5 $4.99 2/15/202321,500 shares $130,075.00 +9.7%1.3%0.1 $6.05 1/31/202319,600 shares $123,480.00 -14.4%1.2%0.1 $6.30 1/15/202322,900 shares $162,819.00 -42.2%1.5%0.1 $7.11 12/30/202239,600 shares $272,844.00 -56.3%2.7%0.1 $6.89 12/15/202290,600 shares $834,426.00 -75.7%N/A0.2 $9.21 11/30/2022373,400 shares $2.50 million +614.0%N/A1 $6.70 11/15/202252,300 shares $208,154.00 -97.4%N/A0.9 $3.98 10/31/20222,040,000 shares $219,708.00 +196.3%N/A0.9 $0.11 10/15/2022688,400 shares $65,535.68 -16.8%N/A0.2 $0.10 9/30/2022827,000 shares $89,316.00 +2.2%N/A0.3 $0.11 9/15/2022808,900 shares $128,210.65 -11.3%N/A0.3 $0.16 8/31/2022911,400 shares $141,358.14 -31.0%N/A0.3 $0.16The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. KTRA Short Interest - Frequently Asked Questions What is Kintara Therapeutics' current short interest? Short interest is the volume of Kintara Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 700,000 shares of KTRA short. Learn More on Kintara Therapeutics' current short interest. Is Kintara Therapeutics' short interest increasing or decreasing? Kintara Therapeutics saw a increase in short interest in April. As of April 15th, there was short interest totaling 700,000 shares, an increase of 6.2% from the previous total of 658,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Kintara Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Kintara Therapeutics: Oragenics, Inc. (2.07%), Xenetic Biosciences Inc (0.22%), Hoth Therapeutics, Inc. (3.39%), Adial Pharmaceuticals, Inc. (26.72%), Lixte Biotechnology Holdings, Inc. (4.59%), TFF Pharmaceuticals, Inc. (2.77%), Enveric Biosciences, Inc. (1.40%), Sonnet BioTherapeutics Holdings, Inc. (15.26%), Protagenic Therapeutics, Inc. (0.28%), Kineta, Inc. (1.23%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Kintara Therapeutics stock? Short selling KTRA is an investing strategy that aims to generate trading profit from Kintara Therapeutics as its price is falling. KTRA shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kintara Therapeutics? A short squeeze for Kintara Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KTRA, which in turn drives the price of the stock up even further. How often is Kintara Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KTRA, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: OGEN Short Interest XBIO Short Interest HOTH Short Interest ADIL Short Interest LIXT Short Interest TFFP Short Interest ENVB Short Interest SONN Short Interest PTIX Short Interest KA Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KTRA) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDems have chosen Biden replacement?Paradigm PressThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange